Radiation Oncology/Bile duct/Clinical Trials

From Wikibooks, open books for an open world
Jump to navigation Jump to search

Front Page: Radiation Oncology | RTOG Trials

Edit this

Bile Duct: Main Page | Resectable Disease | Adjuvant RT | Unresectable Disease | Clinical Trials |

Link to Cancer.gov biliary tract cancer trials. Protocol ID below is cross-linked to the appropriate cancer.gov page.


Phase Protocol ID Protocol Name
Phase III XL119-001 XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects with Advanced Biliary Tumors
Phase II SWS-SAKK-44/02 Phase II Study of Adjuvant Palliative Capecitabine and Gemcitabine in Patients With Locally Advanced or Metastatic Biliary Tract Cancer
Phase II NYWCCC-0803945 Phase II Study of 3-AP (Triapine®) and Gemcitabine in Patients With Unresectable or Metastatic Biliary Duct or Gallbladder Cancer
Phase II FCCC-03042 Phase II Study of Bortezomib as First-Line Systemic Therapy in Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
Phase II NCI-04-C-0273 Phase II Study of Intrahepatic Arterial Infusion of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion in Patients With Unresectable Primary or Metastatic Liver Cancer
Phase II UTMB-NCI-931 Phase II Randomized Study of Immunization With Carcinoembryonic Antigen (CEA) Peptide 1-6D Emulsified in Montanide ISA-51 Versus Dissolved in Sargramostim (GM-CSF) in HLA-A2+ Patients With CEA-Producing Adenocarcinomas of Gastrointestinal Tract Origin
Phase I/II NCCTG-N9943 Phase I/II Study of Gemcitabine and Pemetrexed Disodium in Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer